Compound of novel degradation drug for resisting novel coronavirus and combined application of compound

Through the PROTACs compound MATF1 and its screening method, the problem of inhibiting the main protease of the novel coronavirus was solved, the efficiency and accuracy of drug screening were improved, and efficient and safe anti-novel coronavirus drugs were found, the technical gap was filled, and the new type was provided Effective treatment options for coronavirus.

CN119019381AInactive Publication Date: 2024-11-26YANGTZE DELTA REGION INST (QUZHOU) UNIV OF ELECTRONIC SCI & TECH OF CHINA
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411005226.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-25
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit the main protease of the novel coronavirus, and the drug screening efficiency is low, the antiviral inhibitor is strong, and it is unable to quickly respond to viral mutations.

Method used

Using PROTACs compound MATF1 and its screening method, molecular docking screening was performed through molecular dynamics simulation and AutoDock Vina software, binding energy was calculated, and compounds with anti-novel coronavirus activity were discovered and verified to develop anti-novel coronavirus drugs.

Benefits of technology

Improve the efficiency and accuracy of drug screening, and discovered a new compound MATF1 with high efficiency and safety, which can specifically inhibit the protease of the novel coronavirus, significantly improve the therapeutic effect, reduce side effects, and fill the main target of the novel coronavirus. Technical gaps in protease degradation drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019381A_ABST
    Figure CN119019381A_ABST
Patent Text Reader

Abstract

The invention belongs to but is not limited to the technical field of design of pharmacy and coronavirus infection drugs, and particularly relates to a novel coronavirus-resistant PROTACs compound and application thereof, a plurality of main protease systems are fitted by adopting a molecular dynamics simulation and binding energy calculation mode, and the novel coronavirus-resistant PROTACs compound is obtained according to a scoring function. And a plurality of dimensions such as numerical values in energy calculation and molecular dynamics are compared with a reference compound to analyze that one compound has the activity of degrading main protease so as to have the capability of resisting coronavirus. The invention not only provides a new compound, but also provides an effective methodology for future drug design. Drug design is carried out by adopting molecular dynamics simulation in combination with multiple parameter dimensions such as energy calculation and MD, and a new method is brought to the field of drug research and development.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to but is not limited to the technical fields of design pharmacy and coronavirus infection drugs, and in particular relates to a PROTACs compound against the new coronavirus and its application. Background Art

[0002] The new coronavirus is the seventh coronavirus that can infect humans and belongs to the coronavirus family of RNA viruses. Due to the rapid spread, strong mutation and high mortality rate of this type of virus, as of the end of 2022, according to the WHO report, there have been more than 600 million confirmed cases worldwide and a cumulative death toll of more than 6.61 million.

[0003] Due to the slow pace of drug development and new drug review, there is currently no standard method for effectively treating coronavirus patients. The current treatment for patients with the new coronavirus (COVID-19) is based on the development of SARS-CoV and MERS drugs, and the progress of drug development is being made to explore the feasibility of new uses of old drugs, and to actively promote vaccination, antibody therapy and new drug development.

[0004] Since the outbreak of the novel coronavirus, a large number of neutralizing antibody treatments have entered the clinical stage. However, as the novel coronavirus continues to break out and evolve from new subtypes such as Alpha, Delta, and XBB, the speed of antibody updates has not kept up with the speed of virus mutation. Traditional old drugs such as Remdesivir, Favipiravir, and Ribavirin have not shown significant inhibitory effects on the novel coronavirus at the cellular level during clinical use. So far, a variety of drugs have been used to treat novel coronavirus patients, but drugs that can eradicate the virus or standard treatment methods for COVID-19 patients are still extremely limited.

[0005] In recent decades, natural products have played an important role in drug development and are also the main source of lead compounds. In recent years, marine natural products have attracted extensive attention from a large number of researchers, and a potential drug screening database has been developed.

[0006] In the past three years, researchers have conducted a detailed analysis of the new coronavirus and discovered five major protein regions and functions, namely 16 nonstructural proteins (nsp) and four structural proteins, namely Envelope protein (E protein), Membrane protein (M protein), Nucleocapsid protein (N protein), and Spike protein (S protein). Among them, the new coronavirus encodes NSP5 (3CL Protease or main protease, main protease) of non-structural protein. The main protease is a key virus in the replication process of the new coronavirus. It is a key protein that cuts most NSP proteins from the protein chain of viral replication. Chinese scientists have discovered the structure of the main protease. His41 and Cys145 are the catalytic center of the main protease, which can be said to be the key to affecting the activity of the main protease. Based on the 96% genetic similarity between the sequences of SARS-CoV and SARS-CoV-2, researchers first used inhibitors ML300 and ML188 developed for the main protease of SARS-CoV as virtual screening of inhibitors of COVID-19. The results showed that these two compounds could not bind to the catalytic site of SARS-CoV-2 at the active site. Therefore, drug screening for the main protease is urgently needed.

[0007] Current status of PROTACs drug research: PROTACs (Proteolysis-Targeting Chimera) is an emerging molecular therapeutic entity that works by degrading target proteins. Compared with traditional small molecule inhibitors, PROTACs have many advantages, such as expanding druggable targets, catalytic effects, and overcoming drug resistance. However, PROTACs also face challenges such as large molecular weight and poor oral drugability. Currently, people are overcoming these limitations by optimizing the ligands of target proteins, E3 ubiquitin ligase ligands and linker chains, and developing prodrug strategies.

[0008] PROTACs technology has also received attention in the study of the new coronavirus. Although no PROTACs drugs targeting the main protease of the new coronavirus have entered the clinical research stage, research in this field is deepening.

[0009] Prior art: Using inhibitors to block the main protease of SARS-CoV-2

[0010] The existing technology uses inhibitors ML300 and ML188, which were originally developed against the main protease of SARS-CoV. These inhibitors work by blocking the activity of the main protease, thereby preventing viral replication. The main protease plays a key role in the life cycle of the virus. It is responsible for cleaving newly synthesized viral protein chains into separate functional proteins, which is necessary for viral replication.

[0011] In view of the above analysis, the technical problems that need to be solved urgently in the prior art are:

[0012] 1) Site differences: Although the genetic sequences of SARS-CoV and SARS-CoV-2 are 96% similar, this does not mean that SARS-CoV drugs can effectively inhibit SARS-CoV-2. In fact, research results show that ML300 and ML188 cannot bind to the catalytic site of SARS-CoV-2 at the active site. This is due to changes in protein structure or active sites caused by the 4% genetic difference.

[0013] 2) Challenges in drug screening: Another problem with existing technologies is that drug screening for the new coronavirus faces huge challenges. On the one hand, large-scale compound screening is required in a short period of time to find candidate drugs that can effectively inhibit the main protease of SARS-CoV-2. On the other hand, new drugs must undergo rigorous clinical trials to prove their safety and effectiveness, which requires a lot of time and resources.

[0014] 3) Resistance to antiviral inhibitors: Another problem with existing technologies is that viruses can develop resistance. Long-term use of the same inhibitor will gradually make the virus resistant, resulting in a decrease in drug efficacy. This requires us to continuously develop new inhibitors to cope with the ever-changing viruses.

[0015] Therefore, although some progress has been made in the study of the main protease of the new coronavirus, many challenges are still faced. It is necessary to continue to study more effective inhibitors and discover and verify new candidate drugs through drug screening and clinical trials. Summary of the invention

[0016] In response to the problems existing in the prior art, the present invention provides a compound with an anti-novel coronavirus structure designed based on PROTACs protein degradation technology and its application.

[0017] The present invention is achieved by providing a PROTACs compound against the novel coronavirus.

[0018] Its chemical name is MATF1 and its SMILE format is as follows:

[0019] CC(C)=CCc1c(O)cc(O)c2c(=O)c(-c3ccc(OCCCCCCOc4cccc5c4C(=O)N([C@@H]4CCC(=O)NC4=O)C5=O)c(O)c3)coc12, its molecular formula is C 39 H 38 N2O 11 , average molecular weight 705.25g / mol, compound structure formula:

[0020]

[0021] Another object of the present invention is to provide a method for screening PROTACs compounds against the new coronavirus, characterized in that it comprises the following steps:

[0022] Step 1: Screening docking system;

[0023] Step 2: Collect compounds through PROTAC-DB and PDB;

[0024] Step 3, molecular docking screening was performed using AutoDock Vina software;

[0025] Step 4, comparing the scores with those of the control group compounds;

[0026] Step 5: Conduct molecular dynamics simulation and analysis;

[0027] Step six, calculate the binding energy and analyze and compare.

[0028] Another object of the present invention is to provide a PROTACs compound against the new coronavirus for use in the preparation of drugs against the new coronavirus.

[0029] Another object of the present invention is to provide a pharmaceutical composition for treating COVID-19 including PROTACs compounds against the new coronavirus.

[0030] The medicament includes a pharmaceutically acceptable carrier.

[0031] The medicament includes pharmaceutically acceptable auxiliary ingredients.

[0032] In combination with the above technical solutions and the technical problems solved, the advantages and positive effects of the technical solutions to be protected by the present invention are as follows:

[0033] First, the significant technical advances achieved by the present invention include the following points:

[0034] 1) Discovery of new compounds: The present invention fits multiple main protease systems by molecular dynamics simulation, and compares them with reference compounds in multiple dimensions such as combined energy calculation and MD values, and successfully discovers a new compound with anti-main protease activity.

[0035] 2) Development of new drugs: The discovery of this compound opens the way for the development of drugs for novel coronavirus infection. Its properties make it a strong candidate for the treatment of COVID-19, which is a major technological advancement.

[0036] 3) Effective drug design method: The present invention not only provides new compounds, but also provides an effective methodology for future drug design. By using molecular dynamics simulation, combined with energy calculation and RMSD values ​​and other dimensions for drug design, it brings new insights to the field of drug research and development.

[0037] These technological advances are of great significance for the research and development of drugs against the new coronavirus and can provide new solutions to global public health problems.

[0038] Second, the significant technological advances brought about by the screening method of PROTACs compounds against the new coronavirus include:

[0039] 1) Innovative screening method: This method uses molecular docking technology and molecular dynamics simulation to explore the interaction energy of PROTACs for the first time. This method can predict and analyze the interaction between candidate compounds and the new coronavirus, thereby screening out compounds with antiviral activity.

[0040] 2) Improve screening efficiency: By using AutoDock Vina software for molecular docking screening, this method can screen a large number of candidate compounds in a short time, greatly improving the screening efficiency.

[0041] 3) Accurate evaluation method: By calculating the binding energy and comparing it, this method can accurately evaluate the binding force of candidate compounds to the new coronavirus, which is very important for determining the antiviral activity of candidate compounds.

[0042] Therefore, this method has important application value in the research and development of anti-new coronavirus drugs and will promote technological progress in related fields.

[0043] Third, as auxiliary evidence of the inventiveness of the claims of the present invention, it is also reflected in the following important aspects:

[0044] (1) The expected benefits and commercial value of the technical solution of the present invention after transformation are:

[0045] The technical solution provided by the present invention is a drug degrader for the main protease of the new coronavirus. Once successfully implemented and transformed into practical application, it is expected to provide a new treatment for the global fight against the new crown epidemic. This will not only significantly reduce the threat of the epidemic to human health, but also bring huge economic benefits to society. Specifically, the successful development of new drugs will promote the development of the medical industry, create a large number of employment opportunities, and drive the growth of related industrial chains. In addition, the advent of new drugs will increase patient cure rates, reduce medical costs, and reduce the burden on the global public health system.

[0046] (2) The technical solution of the present invention fills the technical gap in the industry at home and abroad:

[0047] The present invention uses innovative drug screening and design methods to conduct in-depth research on the main protease of the new coronavirus, filling the gap in the field of anti-new coronavirus drug research and development at home and abroad. At present, there is still a lack of degradation drugs for the main protease of the new coronavirus on the market. The technical solution of the present invention is expected to fill this gap and provide a new weapon to fight the new coronavirus epidemic.

[0048] (3) The technical solution of the present invention overcomes technical prejudice:

[0049] The present invention responds to the challenge of the new coronavirus and uses degradable PROTACs drugs to overcome the concentration-dependent effect of traditional drugs, providing a new idea for better solving the prevention and treatment of the new coronavirus, which is rapidly transmitted, highly contagious, and highly lethal.

[0050] Fourth, the present invention proposes a solution based on PROTACs technology to address the problems of poor targeting, poor therapeutic effect, and obvious side effects in the development of existing anti-new coronavirus drugs. Traditional drug development methods are inefficient, and in practical applications, they often face insufficient inhibitory effects of drugs on viral targets, resulting in unsatisfactory treatment effects for patients. In addition, existing drugs have low selectivity for specific proteins of the new coronavirus (such as 3CLpro), which can easily cause side effects and affect the overall health and treatment compliance of patients.

[0051] By adopting a virtual screening method based on protein structure molecular docking, the present invention significantly improves the screening efficiency of anti-new coronavirus drugs. Combined with molecular dynamics simulation technology, the candidate compound MATF1 can be quickly identified and optimized, thereby shortening the drug development cycle. This method not only improves the accuracy of drug screening, but also significantly reduces the waste of experimental resources, improves the overall efficiency of drug development, and enables developers to find effective anti-new coronavirus compounds faster.

[0052] The present invention ensures the high efficiency and safety of compound MATF1 in the treatment of novel coronavirus by precisely designing and optimizing its molecular structure. 39 H 38 N2O 11 , with a molecular weight of 705.25 g / mol, has high targeting, can specifically inhibit or block key proteins of the new coronavirus (such as 3CLpro), and effectively prevent viral replication. Compared with traditional drugs, the PROTACs compounds of the present invention show significant advantages in efficacy and safety, reduce side effects during treatment, and improve patients' treatment compliance and quality of life.

[0053] The present invention has made significant technological progress in the field of anti-new coronavirus drug development. First, through advanced virtual screening and molecular dynamics simulation technology, the efficiency and accuracy of drug screening are improved, and the process of new drug development is significantly accelerated. Secondly, an efficient and safe PROTACs compound MATF1 is developed to specifically inhibit or block the key proteins of the new coronavirus, significantly improving the therapeutic effect. Finally, the stability and bioavailability of the drug are enhanced through pharmaceutically acceptable carriers to ensure its effectiveness and safety in clinical applications. These technological advances have provided strong support for the global fight against the new coronavirus epidemic and promoted technological innovation and development in the field of antiviral drug development. BRIEF DESCRIPTION OF THE DRAWINGS

[0054] Figure 1 This is a flow chart of obtaining anti-novel coronavirus compounds based on a virtual screening method provided in an embodiment of the present invention;

[0055] Figure 2 is a 2D molecular diagram of the compound of formula 1 provided in an embodiment of the present invention;

[0056] Figure 3 is a 2D molecular diagram of the compound of formula 2 provided in an embodiment of the present invention;

[0057] Figure 4 It is a root mean square deviation (RMSD) diagram of the ligand of the compound of formula 1-2 provided in the embodiment of the present invention at 100ns. DETAILED DESCRIPTION

[0058] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0059] Example 1: Screening and verification of MATF1 compounds against novel coronavirus

[0060] In order to develop an effective anti-novel coronavirus drug, the research team used PROTACs technology-based methods for screening and verification.

[0061] 1. Screening and docking system:

[0062] Select key proteins of the new coronavirus (such as 3CLpro) as docking targets.

[0063] 2. Collect compounds:

[0064] Potential PROTACs compounds were collected through PROTAC-DB and PDB databases.

[0065] 3. Molecular docking screening:

[0066] The collected compounds were screened by molecular docking using AutoDock Vina software to determine the binding mode and binding site of the compounds with the target protein.

[0067] 4. Score comparison:

[0068] The screened compounds were scored and compared with the control group compounds, and the compounds with the lowest binding energy and the best binding stability were selected.

[0069] 5. Molecular dynamics simulation and analysis:

[0070] Molecular dynamics simulation was performed on the selected compounds to analyze their stability and binding mode under dynamic conditions.

[0071] 6. Binding energy calculation and analysis comparison:

[0072] The binding energy of the preferred compound to the target protein was calculated to further verify the stability and effectiveness of the binding.

[0073] Through the above screening and verification process, the MATF1 compound (chemical name: MATF1, SMILE format: CC(C)=CCc1c(O)cc(O)c2c(=O)c(-c3ccc(OCCCCCCOc4cccc5c4C(=O)N([C@@H]4CCC(=O)NC4=O)C5=O)c(O)c3)coc12) was identified as a candidate drug with significant anti-novel coronavirus activity.

[0074] Example 2: In vitro experimental verification of MATF1 compound against novel coronavirus

[0075] To further verify the anti-novel coronavirus activity of the MATF1 compound, the research team conducted in vitro experimental verification.

[0076] 1. Cell culture:

[0077] Vero cells infected with the new coronavirus were cultured under appropriate culture conditions.

[0078] 2. Drug treatment:

[0079] The infected cells were treated with MATF1 compounds at different concentrations (1 μM, 5 μM, 10 μM), and control groups (untreated group and positive control group) were set up.

[0080] 3. Virus replication detection:

[0081] The qRT-PCR method was used to detect the viral RNA levels in different treatment groups to evaluate the inhibitory effect of the drug on viral replication.

[0082] 4. Cell viability detection:

[0083] CCK-8 kit was used to detect the cell viability of different treatment groups and evaluate the cytotoxicity of the drugs.

[0084] 5. Data Analysis:

[0085] The viral RNA levels and cell viability of the different treatment groups were compared to determine the effective concentration and safety range of MATF1 compounds.

[0086] The results of in vitro experiments showed that the MATF1 compound significantly inhibited the replication of the new coronavirus at concentrations of 1μM and 5μM, and the cell viability remained at a high level without obvious cytotoxicity. At a concentration of 10μM, although the inhibitory effect was stronger, some cells showed slight toxicity. Therefore, the MATF1 compound was identified as a candidate drug with potential anti-new coronavirus activity and has good application prospects.

[0087] In the present invention, all protein structures and compound structures are from the RCSB PDB database, using Gromacsv2022 and AmberTools 23 to prepare receptor modules and repair missing atoms.

[0088] The object of the present invention is to provide a compound that has a significant inhibitory or blocking effect on the coronavirus main protease and also has stable pharmaceutical characteristics.

[0089] The present invention constructs an in vitro molecular target model, verifies the docking center, performs molecular dynamics tests and calculates binding energy, and finds that Formula 2 has better binding activity and the smallest binding energy than the control group, so the compound can become a potential drug for the treatment of COVID-19. The structural formula of Formula 2 is as follows Figure 3 The structural formula of the control group formula 1 is as shown Figure 2 shown.

[0090] like Figure 1 As shown, the screening method of PROTACs compounds against the new coronavirus provided in the embodiment of the present invention comprises the following steps:

[0091] Step 1: Screening docking system;

[0092] Step 2: Collect compounds through PROTAC-DB and PDB databases;

[0093] Step 3, molecular docking screening was performed by modifying the position of the AutoDock Vina software;

[0094] Step 4, comparing the scores with those of the control group compounds;

[0095] Step 5: Conduct molecular dynamics simulation and analysis;

[0096] Step six, calculate the binding energy and analyze and compare.

[0097] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0098] Example 1 Molecular docking experiment

[0099] Based on the PDB database, the crystal structures of COVID-19 main protease and non-covalent inhibitors were collected.

[0100] Table 1. Non-covalent docking binding main protease data set collected

[0101] No PDB ID Is it stable? 1 6BN8 no 2 6BN7 yes 3 6BN9 no 4 6BNB no 5 6BOY no 6 7PI4 yes 7 8OI no 8 8H no 9 6H0F no 10 6H0G no 11 6LU7 yes 12 7LME yes 13 7LMD yes

[0102] After molecular docking and molecular dynamics verification, among the above 13 systems, only PDBID 7MLE is stable under the conditions. Therefore, the 7LME system parameters are used as the sample parameters for subsequent use.

[0103] The molecular docking simulation was performed using the Vina module in the AutoDock software. In the docking box, the network center is defined as the docking center. The ligand small molecule is scored and analyzed using the Score scoring method. All other parameters are the default values ​​in the AutoDock Vina docking module. The results are shown in Table 2.

[0104] Table 2 Scoring function scores of compounds of formula 1-2

[0105] Score Chemical formula 1 -11.08 Chemical formula 2 -9.6

[0106] Example 2 Molecular dynamics test

[0107] The AMBERff19SB and GAFF positions were used for both proteins and compounds, and the TIP3P water model was used for the system. The solution was solvated using a cubic water box. Periodic boundary conditions (PBC) were used and 0.15 M NaCl was used to neutralize the net charge. The van der Waals interactions were calculated using the LJ 12-6 potential with a cutoff of The long-range electrostatic forces are handled using the PME algorithm. The covalent bonds involving hydrogen atoms are constrained using the SHAKE algorithm. To eliminate unfavorable interatomic contacts, the heavy atoms are first Constraints were applied, and 2500 steps of steepest descent and 2500 steps of conjugate gradient energy minimization were performed. The entire system was then relaxed and 10,000 steps of steepest descent and 10,000 steps of conjugate gradient energy minimization were performed. The system was then gradually heated to 300K using a 20ps NVT simulation. This was followed by a two-step equilibrium phase, first a 200ps constrained heavy atom NPT simulation, followed by a 500ps unconstrained NVT simulation. The temperature was controlled at 300K using a Berendsen thermal bath, and the pressure was controlled at 1atm using a Monte Carlo pressure bath. The coupling constant and relaxation time were both 1ps. Finally, a 100ns NVT simulation was performed with an integration time step of 2fs.

[0108] Based on 100ns molecular dynamics simulation, the RMSD value was calculated to indicate the stability of the interaction between the compound and the protein.

[0109] The results are as follows Figure 4 express.

[0110] 1. Specific application fields or related products of the present invention.

[0111] This product is still in the development stage and no product has been released yet.

[0112] Similar products are mainly used in the anti-cancer field, such as ARV-110 and ARV-471.

[0113] 2. Relevant evidence of the technical effects obtained by the embodiments of the present invention.

[0114] Example 1, MM / PB (GB) SA binding energy test

[0115] Binding free energy calculations were performed on the last stable 2000 snapshots of the molecular dynamics trajectory using the MM / PBSA method in AmberTools 23. For every 100 frames, the binding free energies of the receptor, ligand, and complex were calculated using the “single trajectory” approach.

[0116] The total binding free energy was calculated according to the following formula:

[0117] ΔG bind =ΔG complex -(ΔG receptor +ΔG ligand )

[0118] =ΔE vdw +ΔE ele +ΔG PB +ΔG SA -TΔS

[0119] Among them, ΔG complex , ΔG receptor and ΔG ligand represent the free energy of the complex, receptor, and ligand, respectively; ΔE vdw , ΔE ele , ΔG PB and ΔG SA are the polar and nonpolar parts of van der Waals energy, electrostatic energy and desolvation free energy respectively; TΔS represents the conformational entropy contribution at temperature T. ΔG PB The term is determined by the PB model, and ΔG SA Then ΔG SA =γ×SASA+β, where SASA is the solvent accessible surface area, and the values ​​of constants γ and β are and 0.92 kcal·mol -1 The molecular surface area is given by the radius The results are shown in Table 3.

[0120] Table 3 Calculation results of binding energy of compounds of formula 1-2

[0121] <![CDATA[ΔG bind / GB (kcal / mol)]]> <![CDATA[ΔG bind / PB (kcal / mol)]]> Chemical formula 1 -48.9626±16.0388 -45.7352±12.0768 Chemical formula 2 -51.3200±18.4703 -49.2822±24.8242

[0122] This experiment uses simulation experiments to calculate the binding energy and finds that the activity and binding energy are negatively correlated. In molecular dynamics simulations, MM / PBSA (Molecular Mechanics Poisson-BoltzmannSurface Area) and MM / GBSA (Molecular Mechanics Generalized Born Surface Area) are two commonly used free energy calculation methods for evaluating the binding free energy between biological macromolecules (such as proteins and ligands). Both methods combine molecular mechanics (MM) and solvent effects (described by PB or GB models and SA terms, respectively) to calculate binding free energy. Compared with the PBSA calculation method, GBSA sacrifices the accuracy of the calculation, but is more efficient in calculation. At the same time, the invisible calculation method is suitable for large-scale calculations. In this experiment, no matter which method is used, the binding energy of Chemical Formula 2 is lower than that of Chemical Formula 1, which means that Chemical Formula 2 is more active.

[0123] The above description is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Any modifications, equivalent substitutions and improvements made by any technician familiar with the technical field within the technical scope disclosed by the present invention and within the spirit and principle of the present invention should be covered by the protection scope of the present invention.

Claims

1. A PROTACs compound for resisting novel coronavirus, characterized in that: Its chemical name is MATF1 and its SMILE format is as follows: CC(C)=CCc1c(O)cc(O)c2c(=O)c(-c3ccc(OCCCCCCOc4cccc5c4C(=O)N([C@@H]4CC C(=O)NC4=O)C5=O)c(O)c3)coc12, its molecular formula is C 39 H 38 N2O 11 , average molecular weight 705.25g / mol, compound structure formula:

2. A method for screening PROTACs compounds against the new coronavirus as claimed in claim 1, characterized in that: The following steps are involved: Step 1: Screening docking system; Step 2: Collect compounds through PROTAC-DB and PDB; Step 3, molecular docking screening was performed using AutoDock Vina software; Step 4, comparing the scores with those of the control group compounds; Step 5: Conduct molecular dynamics simulation and analysis; Step six, calculate the binding energy and analyze and compare.

3. Use of a PROTACs compound against the new coronavirus as claimed in claim 1 in the preparation of a drug against the new coronavirus.

4. A drug for treating COVID-19, characterized in that: The drug composition includes the PROTACs compound against the new coronavirus as described in claim 1.

5. The drug for treating COVID-19 according to claim 4, characterized in that The medicament includes a pharmaceutically acceptable carrier.

6. The drug for treating COVID-19 according to claim 4, characterized in that The medicament includes pharmaceutically acceptable auxiliary ingredients.

Citation Information

Patent Citations

  • Diketopiperazine alkaloid compound for resisting novel coronavirus and application of diketopiperazine alkaloid compound

    CN117659052A

  • Compounds and methods for treating viral infections

    US20240016777A1